JPMorgan analyst Benjamin Rossi lowered the firm’s price target on U.S. Physical Therapy (USPH) to $100 from $110 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on USPH:
- US Physical Therapy Updates Investor Presentation
- US Physical Therapy Reports Strong Q3 Growth Amid Challenges
- U.S. Physical Therapy’s Strong Q3 Performance and Positive Outlook Earns Buy Rating from Analyst
- U.S. Physical Therapy Reports Strong Q3 2025 Results
- U.S. Physical Therapy’s Earnings Call Highlights Robust Growth